Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NGEN | EFFECT | neutral | 4/10 | The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on May 26, 2026, under th | May 27, 2026 |
| NONOF | 6-K | neutral | 3/10 | Novo Nordisk filed a 6-K to report ongoing share repurchase activity under a pre-announced program. Since 4 February 202 | May 27, 2026 |
| GLPG | 6-K | neutral | 4/10 | Bank of America crossed above the 5% threshold and now holds a 9.30% total economic interest in Lakefront Biotherapeutic | May 27, 2026 |
| CNSP | EFFECT | bearish | 7/10 | CNS Pharmaceuticals' S-3 shelf registration (File No. 333-296033) became effective on May 26, 2026, as confirmed by this | May 27, 2026 |
| OGN | COURT-RULING | neutral | 4/10 | The court consolidated two securities fraud class actions against Organon & Co. and appointed the Michigan Regional Coun | May 27, 2026 |
| AGMB | PRESS-RELEASE | neutral | 2/10 | Agomab Therapeutics held its Annual General Meeting on May 26, 2026. The press release announces the meeting results but | May 27, 2026 |
| ALGS | PRESS-RELEASE | neutral | 4/10 | Aligos Therapeutics presented 10 posters at the EASL Congress 2026, including new Phase 1 long-term follow-up data for p | May 27, 2026 |
| RCKT | CLUSTER | neutral | 3/10 | CEO Gaurav Shah exercised 76,490 options at $1.69 and immediately sold 55,684 shares on the open market for ~$172K, a cl | May 26, 2026 |
| SER | CLUSTER | mixed | 5/10 | Two directors at Serina Therapeutics made open-market purchases totaling $38K over a 3-day window, representing ~0.13% o | May 26, 2026 |
| KALV | CLUSTER | bearish | 5/10 | Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May 18, 2026, at $26.76/ | May 26, 2026 |
| LQDA | CLUSTER | neutral | 4/10 | CEO Roger Jeffs sold 100,000 shares (~$6.1M) over four consecutive trading days, and director/10% owner Caligan Partners | May 26, 2026 |
| PHVS | CLUSTER | neutral | 4/10 | A cluster of 8 Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.73M in open-market sales over a 7 | May 26, 2026 |
| BCAX | CLUSTER | neutral | 2/10 | Three top BCAX insiders (CEO, CFO, COO) sold a combined $590K in open-market shares over a 7-day window. The CFO's sale | May 26, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | Six Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.38M in stock over a 7-day window. The cluste | May 26, 2026 |
| EDIT | 424B5 | bearish | 7/10 | Editas Medicine is issuing 55,555,556 shares of common stock and accompanying warrants in a $125M underwritten public of | May 26, 2026 |
| KAPA | DEFA14A | neutral | 2/10 | Kairos Pharma filed a DEFA14A supplement correcting the record date for its 2026 Annual Meeting from May 15 to May 18, 2 | May 26, 2026 |
| DTIL | 8-K | neutral | 4/10 | Precision BioSciences held its 2026 annual meeting on May 21, 2026, with roughly 86% of shares represented. Shareholders | May 26, 2026 |
| TRAW | 8-K | neutral | 3/10 | Traws Pharma filed an 8-K to update its at-the-market (ATM) offering program, supplementing its existing $50M ATM agreem | May 26, 2026 |
| LPCN | 8-K | neutral | 4/10 | Lipocine announced the presentation of Phase 3 clinical data for LPCN 1154 (oral brexanolone) for postpartum depression | May 26, 2026 |
| KNSA | 8-K | neutral | 3/10 | Kiniksa entered into a deed of waiver with Baker Bros. Advisors LP, under which Baker Bros. irrevocably waived its conve | May 26, 2026 |
| NBTX | PRESS-RELEASE | neutral | 5/10 | Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raisi | May 26, 2026 |
| BBIO | CLUSTER | bearish | 5/10 | Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day | May 26, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a combined ~$110K in open-market transactions | May 26, 2026 |
| ELAN | CLUSTER | neutral | 3/10 | Elanco's CEO Jeffrey Simmons and another senior executive made open-market purchases totaling $200K on May 15. In additi | May 26, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three top executives (CEO, EVP/GC, CFO) exercised stock options and sold a minimal number of shares on the open market. | May 26, 2026 |
| ELAN | CLUSTER | bullish | 4/10 | Elanco CEO Jeffrey Simmons and another insider made open-market purchases totaling $200K on May 15, 2026, at ~$20.09-$20 | May 26, 2026 |
| EDIT | 8-K | bearish | 7/10 | Editas Medicine priced a dilutive underwritten public offering of 55,555,556 shares of common stock and accompanying war | May 26, 2026 |
| KYMR | 144 | neutral | 2/10 | Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 on May 26, 2026, indicating intent to sell 13,130 s | May 26, 2026 |
| KURA | DEFA14A | neutral | 3/10 | Kura Oncology filed a DEFA14A supplement addressing overboarding concerns regarding director nominee Mary T. Szela, who | May 26, 2026 |
| NGEN | 6-K | bullish | 7/10 | NervGen announced positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study, demo | May 26, 2026 |